Chair, Lahey Health Cancer Institute and Professor, Medicine, Tufts Medical Center
Oncology
Dr. Paul Hesketh, MD
|
|
Give Review
Paul Hesketh, MD is an expert in the field of Oncology. He went to University of Connecticut School of Medicine. University of Connecticut School of Medicine is ranked 60/49 in Research/PrimaryCare. He has 3 awards "Boston Magazine", "Top MD" and "Super Doctor". Paul Hesketh, MD is also a published doctor. He has 33 publication published. The most recent publication is: SWOG S0709: Randomized Phase II Trial of Erlotinib versus Erlotinib Plus Carboplatin/Paclitaxel in Patients with Advanced Non-Small Cell Lung Cancer and Impaired Perfo... He accepts Medicare payments and is registered with Medicare.gov.
Publications
- SWOG S0709: Randomized Phase II Trial of Erlotinib versus Erlotinib Plus Carboplatin/Paclitaxel in Patients with Advanced Non-Small Cell Lung Cancer and Impaired Perfo...
- Antiemetics: American Society of Clinical Oncology Focused Guideline Update.
- Experience With a CT Screening Program for Individuals at High Risk for Developing Lung Cancer.
- Initial Experience With a Free, High-Volume, Low-Dose CT Lung Cancer Screening Program.
- Efficacy and safety of palonosetron as salvage treatment in the prevention of chemotherapy-induced nausea and vomiting in patients receiving low emetogenic chemotherap...
- Aprepitant, dexamethasone, and palonosetron in the prevention of doxorubicin/cyclophosphamide-induced nausea and vomiting.
- Incidence of delayed nausea and vomiting in patients with colorectal cancer receiving irinotecan-based chemotherapy.
- Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update.
- Intercalated Erlotinib-Docetaxel Dosing Schedules Designed to Achieve Pharmacodynamic Separation: Results of a Phase I/II Trial.
- Single-dose intravenous casopitant in combination with ondansetron and dexamethasone for the prevention of oxaliplatin-induced nausea and vomiting: a multicenter, rand...
- Prospective evaluation of the incidence of delayed nausea and vomiting in patients with colorectal cancer receiving oxaliplatin-based chemotherapy.
- Comparison of platinum-based chemotherapy in patients older and younger than 70 years: an analysis of Southwest Oncology Group Trials 9308 and 9509.
- Differential time course of action of 5-HT(3) and NK (1) receptor antagonists when used with highly and moderately emetogenic chemotherapy (HEC and MEC).
- Lung cancer in octogenarians.
- Massive retroperitoneal adrenal hemorrhage secondary to lung cancer metastasis treated by adrenal artery embolization.
- Penny wise, dollar foolish approach to antiemetic use may compromise patient care.
- Aprepitant as salvage antiemetic therapy in breast cancer patients receiving doxorubicin and cyclophosphamide.
- Southwest Oncology Group phase II trial (S0341) of erlotinib (OSI-774) in patients with advanced non-small cell lung cancer and a performance status of 2.
- Chemotherapy-induced nausea and vomiting.
- Erlotinib and vinorelbine in advanced malignant solid tumors: a phase I study.
- Chemotherapy in patients > or = 80 with advanced non-small cell lung cancer: combined results from SWOG 0027 and LUN 6.
- Phase II study of gemcitabine and cisplatin in patients with previously untreated extensive stage small cell lung cancer: Southwest Oncology Group Study 9718.
- Phase II trial of paclitaxel, carboplatin, and topotecan with G-CSF support in previously untreated patients with extensive stage small cell lung cancer: Southwest Onc...
- Sequential vinorelbine and docetaxel in advanced non-small cell lung cancer patients age 70 and older and/or with a performance status of 2: a phase II trial of the So...
- Novel neurokinin-1 antagonists as antiemetics for the treatment of chemotherapy-induced emesis.
- Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemo...
- Understanding the pathobiology of chemotherapy-induced nausea and vomiting. Providing a basis for therapeutic progress.
- A randomized controlled trial of darbepoetin alfa administered as a fixed or weight-based dose using a front-loading schedule in patients with anemia who have nonmyelo...
- Uncommon hematologic malignancies. Case 2. Calcification in untreated primary mediastinal large B-cell lymphoma with sclerosis.
- Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting.
- Adrenal hemorrhage secondary to metastasis from lung cancer.
- Unfavorable therapeutic index of cisplatin/gemcitabine/vinorelbine in advanced non-small-cell lung cancer.
Schools
University Of Connecticut School Of Medicine
St Elizabeth S Medical Center
Boston Medical Center
Doctors Specialties
- Oncology
Accepted Insurances
Awards
- Boston Magazine
- Top MD
- Super Doctor
Education
-
Boston University Medical Center -
St Elizabeth's Medical Center -
University of Connecticut School of Medicine
Hospital
-
Lahey Hospital & Medical Center, Burlington
Drug Facts
| NPI NUMBER | 1265427181 | |
| NPPES Provider LastName | HESKETH | |
| NPPES Provider FirstName | PAUL | |
| NPPES Provider ZIPCode | 018050001 | |
| NPPES Provider State | MA | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 166.0 | |
| Distinct Opioid Count | 2.0 | |
| Opioid Claim Count | 24.0 | |
| Percent Opioid Claims | 14.46 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1265427181 |
| Last Name Of The Provider | HESKETH |
| First Name Of The Provider | PAUL |
| View All |
Similar Doctors
|
Dr. John H. Wolff, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Joyce A. McCaffrey, MD |
|
|
Dr. Todd Shuster, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Corrine Zarwan, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Neela Natarajan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Richard A. Oberfield, MD
This Doctor is OpenDoctor Recommended.
|